Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an update.
Hemogenyx Pharmaceuticals announced that the Institutional Review Board at MD Anderson Cancer Center has approved an amendment to their Phase I trial of HG-CT-1, a CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, to include pediatric patients. This expansion marks a significant milestone, broadening the potential patient population and demonstrating the company’s commitment to advancing treatment options in the pediatric setting, which may enhance their market positioning and support long-term growth.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a clinical stage biopharmaceutical company, publicly traded on the London Stock Exchange, with headquarters in London and US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing several distinct product candidates and platform technologies for innovative product development.
Average Trading Volume: 129,460
Technical Sentiment Signal: Buy
Current Market Cap: £57.9M
Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.